Healthcare

Option Care Health delivers complex infusion therapies outside hospitals through a national platform serving home and ambulatory settings. Strong cash generation, solid returns on capital, and exposure to lower-cost care trends make it a compelling healthcare business to examine.

Envista supplies dental equipment, implants, orthodontics, imaging, and consumables through a broad global platform. Recent growth and cash generation have improved, and its specialty portfolio gives it exposure to durable dental technology trends worth examining closely.

Organon is a global pharma company built around women’s health, established medicines, and biosimilars. The business still generates meaningful cash flow, and future progress hinges on expanding higher-potential segments while improving balance-sheet pressure.

National HealthCare Corporation runs skilled nursing, senior living, and homecare services with a notably strong balance sheet, recovering margins, and rising cash generation. Its appeal lies in resilient care demand paired with unusually disciplined finances.

NeoGenomics provides cancer testing and biopharma services in a healthcare niche with strong long-term demand drivers. Revenue has climbed steadily and cash burn has narrowed, making the path from specialized growth platform to more efficient business the key point to examine.

Maravai LifeSciences supplies critical nucleic acid and biologics testing tools used in drug development and advanced therapies. Its appeal rests on specialized mRNA-related technology and exposure to growing genetic medicine markets as the business works through a post-pandemic reset.

Mesoblast is evolving from a development-stage biotech into a commercial cell-therapy company, driven by the launch of Ryoncil. Revenue growth has surged, giving the business a more tangible foundation and making its next phase of operating progress especially important to watch.